526 related articles for article (PubMed ID: 30049681)
1. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure.
Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma AJ; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
J Am Soc Nephrol; 2018 Sep; 29(9):2279-2285. PubMed ID: 30049681
[No Abstract] [Full Text] [Related]
2. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.
Sicard A; Ducreux S; Rabeyrin M; Couzi L; McGregor B; Badet L; Scoazec JY; Bachelet T; Lepreux S; Visentin J; Merville P; Fremeaux-Bacchi V; Morelon E; Taupin JL; Dubois V; Thaunat O
J Am Soc Nephrol; 2015 Feb; 26(2):457-67. PubMed ID: 25125383
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
[TBL] [Abstract][Full Text] [Related]
4. C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study.
Lee DR; Kim BC; Kim JP; Kim IG; Jeon MY
Transplant Proc; 2018 Dec; 50(10):3452-3459. PubMed ID: 30503524
[TBL] [Abstract][Full Text] [Related]
5. Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies.
Kim JJ; Shaw O; Martin C; Michaelides G; Balasubramaniam R; Sebire NJ; Mamode N; Dorling A; Vaughan R; Marks SD
Pediatr Nephrol; 2018 Jan; 33(1):167-174. PubMed ID: 28918487
[TBL] [Abstract][Full Text] [Related]
6. Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation.
Thammanichanond D; Wiwattanathum P; Mongkolsuk T; Kantachuvesiri S; Worawichawong S; Vallipakorn SA; Kitpoka P
Transplant Proc; 2016 Apr; 48(3):756-60. PubMed ID: 27234729
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
[TBL] [Abstract][Full Text] [Related]
9. Systematic Screening Using Luminex for De Novo C3d Fixing of Class II Donor-Specific Antibodies Is Correlated With Luminex Mean Fluorescence Intensity in Renal Transplant Patients.
Villemaire M; Jouve T; Bourdin A; Janbon B; Pinel N; Tetaz R; Terrier N; Rostaing L; Masson D; Malvezzi P
Exp Clin Transplant; 2019 Aug; 17(4):483-489. PubMed ID: 30346267
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of C3d Assay in Kidney Transplant Recipients With Donor-Specific Anti-Human Leukocyte Antigen Antibodies.
Paek JH; Kwon J; Lim J; Kim Y; Park WY; Jin K; Han S
Transplant Proc; 2022 Mar; 54(2):341-345. PubMed ID: 35033370
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
[TBL] [Abstract][Full Text] [Related]
12. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation.
Smith JD; Ibrahim MW; Newell H; Danskine AJ; Soresi S; Burke MM; Rose ML; Carby M
J Heart Lung Transplant; 2014 Oct; 33(10):1074-82. PubMed ID: 24954882
[TBL] [Abstract][Full Text] [Related]
13. Graft immunologic events in deceased donor kidney transplant recipients with preformed HLA-donor specific antibodies.
Ixtlapale-Carmona X; Arvizu A; De-Santiago A; González-Tableros N; López M; Castelán N; Marino LA; Uribe-Uribe NO; Contreras AG; Vilatobá M; Morales-Buenrostro LE; Alberú J
Transpl Immunol; 2018 Feb; 46():8-13. PubMed ID: 28974434
[TBL] [Abstract][Full Text] [Related]
14. C3d-positive donor-specific antibodies have a role in pretransplant risk stratification of cross-match-positive HLA-incompatible renal transplantation: United Kingdom multicentre study.
Babu A; Khovanova N; Shaw O; Griffin S; Briggs D; Krishnan NS; Fletcher S; Imray C; Seitz A; Baker R; Wellberry-Smith M; Clarke B; Cullen K; Rees T; Edwards F; Burrows E; Howe L; Martin C; Dorling A; Zehnder D; Higgins RM; Mitchell DA; Daga S
Transpl Int; 2020 Sep; 33(9):1128-1139. PubMed ID: 32479670
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of C3d-fixing, preformed donor-specific antibodies in crossmatch-positive living kidney transplantation.
Miyake K; Okumi M; Kakuta Y; Unagami K; Furusawa M; Ishida H; Tanabe K
Transpl Immunol; 2019 Dec; 57():101230. PubMed ID: 31398461
[TBL] [Abstract][Full Text] [Related]
16. Donor-specific B Cell Memory in Alloimmunized Kidney Transplant Recipients: First Clinical Application of a Novel Method.
Wehmeier C; Karahan GE; Krop J; de Vaal Y; Langerak-Langerak J; Binet I; Schaub S; Roelen DL; Claas FHJ; Heidt S;
Transplantation; 2020 May; 104(5):1026-1032. PubMed ID: 31397804
[TBL] [Abstract][Full Text] [Related]
17. Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients.
Bartel G; Wahrmann M; Schwaiger E; Kikić Ž; Winzer C; Hörl WH; Mühlbacher F; Hoke M; Zlabinger GJ; Regele H; Böhmig GA
Transpl Int; 2013 Feb; 26(2):121-30. PubMed ID: 23145861
[TBL] [Abstract][Full Text] [Related]
18. Comparison Between Total IgG, C1q, and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.
Moreno Gonzales MA; Mitema DG; Smith BH; Schinstock CA; Stegall MD; Wakefield LL; Henderson NA; DeGoey SR; Kreuter JD; Gandhi MJ
Transplant Proc; 2017 Nov; 49(9):2031-2035. PubMed ID: 29149956
[TBL] [Abstract][Full Text] [Related]
19. Donor-specific HLA antibody-mediated complement activation is a significant indicator of antibody-mediated rejection and poor long-term graft outcome during lung transplantation: a single center cohort study.
Roux A; Thomas KA; Sage E; Suberbielle-Boissel C; Beaumont-Azuar L; Parquin F; Le Guen M; Harre N; Hamid AM; Reed EF
Transpl Int; 2018 Jul; 31(7):761-772. PubMed ID: 29537702
[TBL] [Abstract][Full Text] [Related]
20. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
